Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Lactoferrin  COVID-19 treatment studies for Lactoferrin  C19 studies: Lactoferrin  Lactoferrin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case -59% Improvement Relative Risk Case -23% c19early.org/lf Navarro et al. NCT04526821 LF-COVID Lactoferrin RCT Prophylaxis Favors lactoferrin Favors control
Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID)
Navarro et al., BioMetals, doi:10.1007/s10534-022-00477-3, LF-COVID, NCT04526821 (history)
Navarro et al., Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded.., BioMetals, doi:10.1007/s10534-022-00477-3, LF-COVID, NCT04526821
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Early terminated low-risk patient prophylaxis RCT in Peru, showing no significant difference in cases with lactoferrin. There were no moderate or severe cases.
risk of symptomatic case, 58.7% higher, RR 1.59, p = 0.34, treatment 11 of 104 (10.6%), control 7 of 105 (6.7%).
risk of case, 23.4% higher, RR 1.23, p = 0.65, treatment 11 of 104 (10.6%), control 9 of 105 (8.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Navarro et al., 7 Dec 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Peru, peer-reviewed, median age 37.0, 14 authors, study period October 2020 - February 2021, trial NCT04526821 (history) (LF-COVID).
Contact: theresa.ochoa@upch.pe.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperLactoferrinAll
Abstract: Biometals https://doi.org/10.1007/s10534-022-00477-3 Bovine lactoferrin for the prevention of COVID‑19 infection in health care personnel: a double‑blinded randomized clinical trial (LF‑COVID) Rafaella Navarro · Jose Luis Paredes · Lourdes Tucto · Carlos Medina · Eddie Angles‑Yanqui · Juan Carlos Nario · Jorge Ruiz‑Cabrejos · Juan Luis Quintana · Kevin Turpo‑Espinoza · Fernando Mejia‑Cordero · Meylin Aphang‑Lam · Jorge Florez · Gabriel Carrasco‑Escobar · Theresa Jean Ochoa Received: 30 March 2022 / Accepted: 24 November 2022 © The Author(s), under exclusive licence to Springer Nature B.V. 2022 Abstract Lactoferrin (LF) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to determine the effect of bovine lactoferrin (bLF) in the prevention of SARS-CoV-2 infection in health care personnel. A randomized, double-blinded, placebo-controlled clinical trial was conducted in two tertiary hospitals that provide care to patients with SARS-CoV-2 infection in Lima, Peru. Daily supplementation with 600 mg of enteral bLF versus placebo for 90 days was compared. Participants were weekly screened for symptoms suggestive of SARS-CoV-2 infection and molecular testing was performed on Navarro Rafaella and Paredes Jose Luis have contributed equally to this work and share first authorship. Supplementary Information The online version contains supplementary material available at https://​doi.​ org/​10.​1007/​s10534-​022-​00477-3. R. Navarro · J. L. Paredes · L. Tucto · J. C. Nario · J. L. Quintana · K. Turpo‑Espinoza · T. J. Ochoa (*) Laboratorio de Infectologia Pediátrica, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru e-mail: theresa.ochoa@upch.pe R. Navarro · J. L. Paredes · C. Medina · E. Angles‑Yanqui · J. C. Nario · J. L. Quintana · K. Turpo‑Espinoza · F. Mejia‑Cordero · M. Aphang‑Lam · J. Florez · T. J. Ochoa Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, Peru suspected episodes. A serological test was obtained from all participants at the end of the intervention. The main outcome included symptomatic and asymptomatic cases. A sub-analysis explored the time to symptomatic infection. Secondary outcomes were the severity, frequency, and duration of symptomatic infection. The study was prematurely cancelled due to the availability of vaccines against SARS-CoV-2 in Peru. 209 participants were enrolled and randomized, 104 received bLF and 105 placebo. SARSCoV-2 infection occurred in 11 (10.6%) participants assigned to bLF and in 9 (8.6%) participants assigned to placebo without significant differences (Incidence Rate Ratio = 1.23, 95%CI 0.51–3.06, p-value = 0.64). There was no significant effect of bLF on time to symptomatic infection (Hazard Ratio = 1.61, 95%CI 0.62–4.19, p-value = 0.3). There were no significant C. Medina · F. Mejia‑Cordero Hospital Cayetano Heredia, Lima, Peru E. Angles‑Yanqui · M. Aphang‑Lam · J. Florez Hospital Nacional Arzobispo Loayza, Lima, Peru J. Ruiz‑Cabrejos · G. Carrasco‑Escobar Laboratorio de Innovación en Salud, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru T. J. Ochoa School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA Vol.: (0123456789) 13 Biometals differences in secondary outcomes. A significant effect of bLF in preventing SARS-CoV-2 infection was not..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit